» Articles » PMID: 18509475

Rabies Post-exposure Prophylaxis in the Philippines: Health Status of Patients Having Received Purified Equine F(ab')(2) Fragment Rabies Immunoglobulin (Favirab)

Overview
Date 2008 May 30
PMID 18509475
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recommended treatment for severe rabies exposure in unvaccinated individuals includes wound cleaning, administration of rabies immunoglobulins (RIG), and rabies vaccination. We conducted a survey of rabies treatment outcomes in the Philippines.

Methods: This was a case series involving 7,660 patients (4 months to 98 years of age) given purified equine RIG (pERIG) at the Research Institute for Tropical Medicine (Muntinlupa, Philippines) from July 2003 to August 2004 following Category II or III exposures. Data on local and systemic adverse reactions (AR) within 28 days and biting animal status were recorded; outcome data were obtained by telephone or home visit 6-29 months post-exposure.

Results: Follow-up data were collected for 6,464 patients. Of 151 patients with laboratory-confirmed rabies exposure, 143 were in good health 6-48 months later, seven could not be contacted, and one 4-year-old girl died. Of 16 deaths in total, 14 were unrelated to rabies exposure or treatment. Two deaths were considered PEP failures: the 4-year old girl, who had multiple deep lacerated wounds from a rabid dog of the nape, neck, and shoulders requiring suturing on the day of exposure, and an 8-year-old boy who only received rabies PEP on the day of exposure.

Conclusions: This extensive review of outcomes in persons with Category III exposure shows the recommended treatment schedule at RITM using pERIG is well tolerated, while survival of 143 laboratory-confirmed rabies exposures confirms the intervention efficacy. Two PEP intervention failures demonstrate that sustained education and training is essential in rabies management.

Citing Articles

Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab') fragments.

Findlay-Wilson S, Easterbrook L, Smith S, Pope N, Aldridge M, Humphries G Sci Rep. 2023; 13(1):13912.

PMID: 37626085 PMC: 10457378. DOI: 10.1038/s41598-023-40277-4.


Effect of Phone Text Message Reminders on Compliance with Rabies Post-Exposure Prophylaxis following Dog Bites in Rural Kenya.

Chuchu V, Mutono N, Bichanga P, Kitala P, Ksee D, Muturi M Vaccines (Basel). 2023; 11(6).

PMID: 37376501 PMC: 10303647. DOI: 10.3390/vaccines11061112.


Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.

Li E, Han Q, Bi J, Wei S, Wang S, Zhang Y Front Immunol. 2023; 14:1066730.

PMID: 36875106 PMC: 9981790. DOI: 10.3389/fimmu.2023.1066730.


Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review.

Parrera G, Astacio H, Tunga P, Anderson D, Hall C, Richardson J Toxins (Basel). 2022; 14(1).

PMID: 35050996 PMC: 8778610. DOI: 10.3390/toxins14010019.


Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.

Salinas F, Marelli B, Sanguineti S, Goldbaum F, Munoz L, Etchevers L Toxicol Appl Pharmacol. 2021; 434:115796.

PMID: 34785274 PMC: 8590615. DOI: 10.1016/j.taap.2021.115796.


References
1.
Chantanakajornfung A, Naraporn N, Khumphai W, Bejavongkulchai M, Mitmoonpitak C, Wilde H . A study of human rabies immune globulin manufactured by the Thai Red Cross. Vaccine. 1999; 17(7-8):979-81. DOI: 10.1016/s0264-410x(98)00314-4. View

2.
Suwansrinon K, Jaijaroensup W, Wilde H, Sitprija V . Is injecting a finger with rabies immunoglobulin dangerous?. Am J Trop Med Hyg. 2006; 75(2):363-4. View

3.
LANG J, Attanath P, Quiambao B, Singhasivanon V, Chanthavanich P, Montalban C . Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop. 1998; 70(3):317-33. DOI: 10.1016/s0001-706x(98)00038-2. View

4.
Sampath G, Parikh S, Sangram P, Briggs D . Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals. Vaccine. 2005; 23(9):1102-5. DOI: 10.1016/j.vaccine.2004.08.036. View

5.
Hanlon C, Niezgoda M, Morrill P, Rupprecht C . The incurable wound revisited: progress in human rabies prevention?. Vaccine. 2001; 19(17-19):2273-9. DOI: 10.1016/s0264-410x(00)00516-8. View